Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

220 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
Hartmann JT, Haap M, Kopp HG, Lipp HP. Hartmann JT, et al. Curr Drug Metab. 2009 Jun;10(5):470-81. doi: 10.2174/138920009788897975. Curr Drug Metab. 2009. PMID: 19689244 Review.
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L. Benjamin RS, et al. Among authors: hartmann jt. Cancer Chemother Pharmacol. 2011 Jul;68(1):69-77. doi: 10.1007/s00280-010-1431-9. Epub 2010 Sep 14. Cancer Chemother Pharmacol. 2011. PMID: 20838998 Free PMC article. Clinical Trial.
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A. Potthoff K, et al. Among authors: hartmann jt. Ann Oncol. 2011 Mar;22(3):524-535. doi: 10.1093/annonc/mdq387. Epub 2010 Aug 13. Ann Oncol. 2011. PMID: 20709812
Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005.
Hartmann JT, Bauer S, Egerer G, Horger MS, Kopp HG, Grünwald V, Mayer F. Hartmann JT, et al. Invest New Drugs. 2013 Feb;31(1):167-74. doi: 10.1007/s10637-012-9840-8. Epub 2012 Jul 5. Invest New Drugs. 2013. PMID: 22763609 Clinical Trial.
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.
Hartmann JT, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm MM, Heeger S, Bokemeyer C. Hartmann JT, et al. Invest New Drugs. 2013 Jun;31(3):661-8. doi: 10.1007/s10637-012-9856-0. Epub 2012 Jul 26. Invest New Drugs. 2013. PMID: 22832803 Clinical Trial.
Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.
Schlemmer M, Bauer S, Schütte R, Hartmann JT, Bokemeyer C, Hosius C, Reichardt P. Schlemmer M, et al. Among authors: hartmann jt. Eur J Med Res. 2011 May 12;16(5):206-12. doi: 10.1186/2047-783x-16-5-206. Eur J Med Res. 2011. PMID: 21719393 Free PMC article. Clinical Trial.
Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.
Haap M, Gallwitz B, Thamer C, Müssig K, Häring HU, Kanz L, Hartmann JT. Haap M, et al. Among authors: hartmann jt. J Endocrinol Invest. 2007 Sep;30(8):688-92. doi: 10.1007/BF03347451. J Endocrinol Invest. 2007. PMID: 17923802
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Hartmann JT, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. Hartmann JT, et al. Invest New Drugs. 2006 May;24(3):249-53. doi: 10.1007/s10637-005-3537-1. Invest New Drugs. 2006. PMID: 16133789 Clinical Trial.
[Platinum compounds: metabolism, toxicity and supportive strategies].
Lipp HP, Hartmann JT. Lipp HP, et al. Among authors: hartmann jt. Praxis (Bern 1994). 2005 Feb 9;94(6):187-98. doi: 10.1024/0369-8394.94.6.187. Praxis (Bern 1994). 2005. PMID: 15754530 Review. German.
Follow up after primary treatment: curable diseases treated non-surgically.
Bokemeyer C, Kollmannsberger C, Hartmann JT, Kanz L. Bokemeyer C, et al. Among authors: hartmann jt. Ann Oncol. 2000;11 Suppl 3:73-8. doi: 10.1093/annonc/11.suppl_3.73. Ann Oncol. 2000. PMID: 11079122 Review. No abstract available.
220 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback